Carboplatin in Neoadjuvant Chemotherapy for Triple‑Negative Breast Cancer: No EFS Gain but an Overall Survival Signal Driven by Premenopausal Patients
Posted innews Oncology

Carboplatin in Neoadjuvant Chemotherapy for Triple‑Negative Breast Cancer: No EFS Gain but an Overall Survival Signal Driven by Premenopausal Patients

A phase III trial found that adding weekly carboplatin to taxane‑anthracycline neoadjuvant chemotherapy did not significantly improve event‑free survival overall but was associated with improved overall survival, with benefits concentrated in premenopausal women; hematologic toxicity increased.
Preoperative PAXG Improves Event‑Free Survival over mFOLFIRINOX in Resectable and Borderline Resectable Pancreatic Cancer: First Randomisation Results from PACT‑21 CASSANDRA
Posted innews Oncology

Preoperative PAXG Improves Event‑Free Survival over mFOLFIRINOX in Resectable and Borderline Resectable Pancreatic Cancer: First Randomisation Results from PACT‑21 CASSANDRA

In the multicentre phase 3 PACT‑21 CASSANDRA trial, preoperative PAXG significantly prolonged event‑free survival versus mFOLFIRINOX in resectable and borderline resectable pancreatic ductal adenocarcinoma, with comparable high‑grade toxicity and overall tolerability.